Articles found by an AI-assisted PubMed search that may be missing from CancerImmunoDB, shared so that curators and users can see what is being considered.
Why this exists: the database holds only about 10 articles a year for 2021–2024, and a plain PubMed search cannot judge whether a paper fits the scope.
| Year | Screened | Likely relevant |
|---|---|---|
| 2026 | 99 | 61 |
| 2025 | 100 | 81 |
| 2024 | 98 | 72 |
| 2023 | 92 | 45 |
| 2022 | 100 | 52 |
| 2021 | 85 | 49 |
360 articles shown. “In the database” counts the entries the database already has for each drug the AI named (cell line / animal / patient).
| PMID | Year | Article | Drugs | Study type | Cancer type | In the database | Curator status |
|---|---|---|---|---|---|---|---|
| 36131607 | 2022 | Resveratrol reduces lactate production and modifies the ovarian cancer immune microenvironment. Neoplasma Likely relevant The study tests resveratrol and PD-1 blockade in vitro and in vivo, measuring effects on lactate production, Treg suppressive function, and anti-tumor immunity. | resveratrol; PD-1 blockade | Mixed | ovarian cancer | resveratrol 8/0/0; PD-1 blockade 0/0/0 | Awaiting curator check |
| 36159865 | 2022 | Immune-related RNA signature predicts outcome of PD-1 inhibitor-combined GEMCIS therapy in advanced intrahepatic cholangiocarcinoma. Frontiers in immunology Likely relevant The study assays immunogenic properties of gemcitabine-based chemotherapy and evaluates immune-related molecules using multiplexed immunofluorescence and flow cytometry in patients treated with GEMCIS and sintilimab. | gemcitabine; cisplatin; sintilimab | Patient | advanced intrahepatic cholangiocarcinoma | gemcitabine 30/23/10; cisplatin 18/3/11; sintilimab 0/0/1 | Awaiting curator check |
| 36165836 | 2022 | Reshaping hypoxia and silencing CD73 via biomimetic gelatin nanotherapeutics to boost immunotherapy. Journal of controlled release : official journal of the Controlled Release Society Likely relevant The study tests biomimetic gelatin nanotherapeutics delivering CD73siRNA combined with PD-L1 blockade in mouse models and measures immune cell populations and cytokines. | CSG@B16F10; CD73siRNA; PD-L1 checkpoint blockade | Animal | melanoma | CSG@B16F10 0/0/0; CD73siRNA 0/0/0; PD-L1 checkpoint blockade 0/0/0 | Awaiting curator check |
| 36243711 | 2022 | TiSe2-mediated sonodynamic and checkpoint blockade combined immunotherapy in hypoxic pancreatic cancer. Journal of nanobiotechnology Likely relevant Tests TiSe2-mediated sonodynamic therapy combined with anti-PD-1 in mice and measures immune cell infiltration, cytokine secretion, and DC maturation. | TiSe2 nanosheets; anti-PD-1 | Animal | pancreatic cancer | TiSe2 nanosheets 0/0/0; anti-PD-1 14/36/0 | Awaiting curator check |
| 36256824 | 2022 | FLASH X-ray spares intestinal crypts from pyroptosis initiated by cGAS-STING activation upon radioimmunotherapy. Proceedings of the National Academy of Sciences of the United States of America Likely relevant Tests radioimmunotherapy combining FLASH X-ray and anti-PD-L1 in mice, evaluating CD8+ T cell-mediated immune responses and cGAS-STING activation. | anti-PD-L1 | Animal | unspecified | anti-PD-L1 0/15/0 | Awaiting curator check |
| 36263619 | 2022 | PD‑L1 mediates triple‑negative breast cancer evolution via the regulation of TAM/M2 polarization. International journal of oncology Likely relevant Tests alpha-PD-L1 in vitro and in vivo, measuring its effect on TAM/M2 polarization and STAT3 signaling. | alpha-PD-L1 | Mixed | triple-negative breast cancer | alpha-PD-L1 0/0/0 | Awaiting curator check |
| 36288869 | 2022 | Development of Novel Small Antitumor Compounds Inhibiting PD-1/PD-L1 Binding. Anticancer research Likely relevant The study tests novel small molecule inhibitors of PD-1/PD-L1 in vivo using a humanized mouse model and assesses CD8+ T cell infiltration. | SCL-1; SCL-2; anti-PD-1 antibody | Animal | squamous cell carcinoma | SCL-1 0/0/0; SCL-2 0/0/0; anti-PD-1 antibody 0/2/0 | Awaiting curator check |
| 36322632 | 2022 | Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade. Science translational medicine Likely relevant The study tests an antibody-sialidase conjugate and immune checkpoint blockade in murine models, demonstrating macrophage repolarization and enhanced adaptive antitumor immunity. | antibody-sialidase conjugate; immune checkpoint blockade (ICB) | Animal | cancer | antibody-sialidase conjugate 0/0/0; immune checkpoint blockade (ICB) 0/0/0 | Awaiting curator check |
| 36333531 | 2022 | Reprogramming of pancreatic adenocarcinoma immunosurveillance by a microbial probiotic siderophore. Communications biology Likely relevant Tests ferrichrome and anti-PD-L1 in a mouse model and measures macrophage reprogramming and CD8+ T cell infiltration. | ferrichrome; anti-PD-L1 | Animal | pancreatic cancer | ferrichrome 0/0/0; anti-PD-L1 0/15/0 | Awaiting curator check |
| 36372138 | 2022 | Combination of photosensitizer and immune checkpoint inhibitors for improving the efficacy of tumor immunotherapy. International journal of pharmaceutics Likely relevant The study tests a combination of photosensitizer and immune checkpoint inhibitor delivery systems and measures immune cell activation and pathway blockade. | PD-L1McAb&HMME@Clip; immune checkpoint inhibitors | Unclear | tumors | PD-L1McAb&HMME@Clip 0/0/0; immune checkpoint inhibitors 0/0/0 | Awaiting curator check |
| 36713444 | 2022 | Releasing the restraints of Vγ9Vδ2 T-cells in cancer immunotherapy. Frontiers in immunology Likely relevant The study experimentally tests zoledronic acid and Bacillus Calmette-Guérin on Vγ9Vδ2 T-cells and tumour cell co-cultures, measuring checkpoint receptor expression, cytotoxicity, and cytokine production. | zoledronic acid; Bacillus Calmette-Guérin | Cell line | unspecified tumour cell targets | zoledronic acid 0/0/0; Bacillus Calmette-Guérin 0/0/0 | Awaiting curator check |
| 33046519 | 2021 | Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling. Clinical cancer research : an official journal of the American Association for Cancer Research Likely relevant Evaluates combinations of the SHP2 inhibitor TNO155 and other targeted/immunotherapy drugs in vitro and in vivo, reporting effects on tumor-associated macrophages. | TNO155; nazartinib; BRAF inhibitor; MEK inhibitor; KRASG12C inhibitor; ribociclib; anti-PD-1 antibody | Mixed | lung and colorectal cancer | TNO155 0/0/0; nazartinib 0/0/0; BRAF inhibitor 0/2/2; MEK inhibitor 21/5/1 | Awaiting curator check |
| 33144318 | 2021 | Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma. Gut Likely relevant Tests cabozantinib, MLN0128, and anti-PD-L1 in cell lines and mouse models, assessing tumor-infiltrating T cells and PD-L1 expression. | cabozantinib; MLN0128; anti-PD-L1 antibody | Mixed | hepatocellular carcinoma | cabozantinib 15/4/1; MLN0128 0/0/0; anti-PD-L1 antibody 0/1/0 | Awaiting curator check |
| 33257429 | 2021 | Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research Likely relevant The study experimentally tests oncolytic adenoviruses and anti-PD-1 checkpoint blockade in murine orthotopic glioblastoma and reports their effects on tumor-infiltrating immune cells and T-cell cytotoxicity. | ICOVIR17; ICOVIR15; anti-PD-1 | Animal | glioblastoma | ICOVIR17 0/0/0; ICOVIR15 0/0/0; anti-PD-1 14/36/0 | Awaiting curator check |
| 33276030 | 2021 | CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma. Journal of hepatology Likely relevant Tests CD40 agonist, anti-PD-1, and chemotherapy in murine CCA models and measures immune cell infiltration and activation via FACS. | IgG control; CD40 agonistic antibody; anti-PD-1; gemcitabine; cisplatin | Animal | intrahepatic cholangiocarcinoma | IgG control 0/0/0; CD40 agonistic antibody 0/0/0; anti-PD-1 14/36/0; gemcitabine 30/23/10 | Awaiting curator check |
| 33311600 | 2021 | Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan/JQ1 for chemo-immunotherapy. Acta pharmacologica Sinica Likely relevant The study experimentally tests liposomal irinotecan/JQ1 codelivery targeted with anti-PD-L1 in tumor-bearing mice and measures immune readouts such as DC maturation, CD8+ T cells, IFN-gamma, and Tregs. | irinotecan; JQ1; anti-PD-L1 | Animal | colorectal cancer | irinotecan 30/2/0; JQ1 14/6/0; anti-PD-L1 0/15/0 | Awaiting curator check |
| 33320838 | 2021 | Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade. JCI insight Likely relevant The study evaluates ketogenic diet/3-hydroxybutyrate and checkpoint blockade in mice, measuring changes in PD-L1 expression on myeloid cells and CXCR3+ T cell expansion. | anti-PD-1; anti-CTLA-4; 3-hydroxybutyrate | Animal | general tumors | anti-PD-1 14/36/0; anti-CTLA-4 1/10/7; 3-hydroxybutyrate 0/0/0 | Awaiting curator check |
| 33338425 | 2021 | DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity. Cancer cell Likely relevant The study evaluates anti-PD-1 therapy in tumor models, assessing cytosolic DNA sensing, IFN-beta production, and T cell infiltration. | anti-PD-1 | Animal | mismatch repair-deficient cancer | anti-PD-1 14/36/0 | Awaiting curator check |
| 33357452 | 2021 | Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade. Cancer cell Likely relevant The study tests chemotherapy (cyclophosphamide, oxaliplatin) and checkpoint blockade (anti-PD-L1) in a mouse lung cancer model, measuring effects on CAR-T cell infiltration and macrophage activation. | cyclophosphamide; oxaliplatin; anti-PD-L1 | Animal | lung adenocarcinoma | cyclophosphamide 5/15/9; oxaliplatin 12/5/2; anti-PD-L1 0/15/0 | Awaiting curator check |
| 33408092 | 2021 | Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy. Journal for immunotherapy of cancer Likely relevant The study experimentally tests Flt3L, polyI:C, anti-CD40, anti-PD-1, and anti-TIM-3 in tumor-bearing mice and measures their effects on dendritic cells, T cell numbers, activation, checkpoint expression, and cytokine production. | Fms-related tyrosine 3 ligand; polyI:C; anti-CD40; anti-PD-1; anti-TIM-3 | Animal | melanoma | Fms-related tyrosine 3 ligand 0/0/0; polyI:C 0/0/0; anti-CD40 7/5/0; anti-PD-1 14/36/0 | Awaiting curator check |
| 33421711 | 2021 | Phenolic immunogenic cell death nanoinducer for sensitizing tumor to PD-1 checkpoint blockade immunotherapy. Biomaterials Likely relevant Tests a phenolic ICD inducer nanoparticle containing doxorubicin in tumor-bearing models and evaluates immune cell infiltration and maturation. | doxorubicin | Animal | tumor models | doxorubicin 22/9/0 | Awaiting curator check |
| 33453147 | 2021 | Inhibition of vascular adhesion protein-1 enhances the anti-tumor effects of immune checkpoint inhibitors. Cancer science Likely relevant The study experimentally tests a vascular adhesion protein-1 inhibitor (U-V296) and immune checkpoint inhibitors in murine colon cancer models and measures multiple immune cell populations, cytokines, and T cell functions. | U-V296; immune checkpoint inhibitors | Animal | colon cancer | U-V296 0/0/0; immune checkpoint inhibitors 0/0/0 | Awaiting curator check |
| 33462141 | 2021 | Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer. Journal for immunotherapy of cancer Likely relevant The study tests antibodies targeting IL-17A and PD-1 in mouse models and examines their effects on CD8+ T cells, PD-L1 levels, and myeloid-derived suppressor cells. | anti-IL-17A; anti-PD-1 | Mixed | colorectal cancer | anti-IL-17A 0/0/0; anti-PD-1 14/36/0 | Awaiting curator check |
| 33502118 | 2021 | Cancer-on-a-Chip for Modeling Immune Checkpoint Inhibitor and Tumor Interactions. Small (Weinheim an der Bergstrasse, Germany) Likely relevant Tests anti-PD-1 antibodies on cancer spheroids and T cells in a microfluidic device, measuring T cell infiltration and IL-2 secretion. | anti-PD-1 | Cell line | breast cancer | anti-PD-1 14/36/0 | Awaiting curator check |
| 33504617 | 2021 | Blockade of PD-1/PD-L1 Pathway Enhances the Antigen-Presenting Capacity of Fibrocytes. Journal of immunology (Baltimore, Md. : 1950) Likely relevant Examines the function of human and murine fibrocytes and demonstrates that PD-L1 blockade enhances CD8+ T cell proliferation. | anti-CD86; anti-CD54; anti-PD-L1 | Mixed | lung adenocarcinoma | anti-CD86 0/0/0; anti-CD54 0/0/0; anti-PD-L1 0/15/0 | Awaiting curator check |